Outcomes of Early Simultaneous Removal of Ureteric Stent With Indwelling Urethral Catheter After Kidney Transplant in Pediatric Recipients: A 10-Year Review.

Objectives: A ureteric stent is routinely placed to minimize urological complications during kidney transplant. However, some complications may occur in association with the ureteric stent, such as urinary tract infections, and the optimal duration for stent placement is unclear. We reviewed the outcomes following early simultaneous removal of the ureteric stent with the urethral catheter in pediatric kidney transplant recipients.

Metabolite diagnosis of primary hyperoxaluria type 3.

Background: Primary hyperoxaluria type 3 (PH3) is a recently described cause of childhood renal calculi. It results from mutations in the HOGA1 gene and most cases have been diagnosed after clinical ascertainment, exclusion of other genetic hyperoxalurias and mutation testing. Metabolite testing has not been widely applied but holds promise for the rapid screening and diagnosis of patients who are not specifically suspected to have PH3.

4-hydroxyglutamate is a biomarker for primary hyperoxaluria type 3.

Primary hyperoxaluria type 3 (PH3) is a recently identified inborn error of 4-hydroxyproline metabolism causing kidney stone disease. Diagnosis to date has relied on mutation detection. The excretion of 4-hydroxyglutamate (4OHGlu) was investigated in controls and a cohort of nine patients with PH3 and their parents using flow injection tandem mass spectrometry.

Treating trismus with dynamic splinting: a case report.

Trismus is a pathological condition of the muscles of mastication which commonly affects patients who have undergone dental procedures, oral surgery, and radiation therapy for head and neck cancer. The purpose of this case report is to describe the use of dynamic splinting, a noninvasive modality to reduce trismus which occurred in a patient following multiple dental procedures. A 26 year old man of African descent was referred for severe trismus and pain following three dental procedures on the lower right molars.

The Fremantle lead study part 2.

Aim: A 1993 study of blood lead levels (BLLs) in pre-schoolers living in Fremantle showed 25% had BLLs >or= 10 microg/dL. This study compares the 1993 BLLs with a sample of contemporary Fremantle pre-schoolers.

Methods: Pre-schoolers (0-5 years) living in the Fremantle area were recruited from hospital and community settings during 2005.

Blood pressure measurements on children in the emergency department.

Background: There is no consensus on routine blood pressure (BP) measurement for children presenting to the ED. By contrast, BP measurements are performed routinely in adult ED. With increasing childhood obesity, and the knowledge that elevated BP in childhood correlates with hypertension in adulthood, routine BP measurement in children should be considered.

Management of septic shock in childhood.

Objective: The object of this review is to discuss the recognition and treatment of septic shock in children based on principles of resuscitation, antibiotic use and recent therapeutic advances.

Methods: A comprehensive literature search combining these

Methods: on-line searches of Ovid, PubMed, and Medline; hand searches of 25 international journals; a trawl of 26 textbooks; searches of reference lists of pertinent articles; and scans of abstracts of recent international meetings. Various national and international units were contacted with regard to current research therapeutic strategies, both published and unpublished.

Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab.

Childhood autoimmune hemolytic anemia (AIHA) of the warm type is usually successfully managed with corticosteroids and/or immunoglobulin infusions. In a small proportion of patients AIHA follows a more severe and protracted pathway resulting in the use of immunosuppressive therapy and frequently culminating with the need for splenectomy. Rituximab is an anti-CD20 (B-cell) monoclonal antibody used for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma.